Durnovo Evgenia Alexandrovna, Furman Irina Vladimirovna, Pushkin Sergey Yurievitch, Maslennikov Igor Alexeevitch, Bondar Olga Grigorievna, Ivanitsky Genrih Romanovitch
Nizhny Novgorod State Medical Academy (Chairperson: Prof. Vyacheslav V. Shkarin), Russia.
SPF "Perftoran" (Chairperson: Sergey Yurievitch Pushkin), Pushchino, Moscow Region, Russia.
J Craniomaxillofac Surg. 2008 Apr;36(3):161-172. doi: 10.1016/j.jcms.2007.07.012. Epub 2008 Mar 19.
The study was carried out to ascertain the effects of perftoran in the treatment of facial and Dupuytren's phlegmons with simultaneous estimation of the general reaction in humans.
Seventy-six patients with facial or Dupuytren's phlegmons were divided into 2 groups, one with mild and the other with a severe course of the inflammatory process. Each group was subdivided into 2 subgroups: one control group with "traditional" treatment and one study group where the traditional treatment was supplemented with perftoran. Perftoran was given to both study groups (1-3 ml/kg body weight, single intravenous injection) immediately after surgery plus further daily local wound treatment with perftoran until the end of exudation. The condition of the purulent wound and its reparative processes, the state of free-radical oxidation processes, antihypoxia and effects of perftoran were evaluated at various treatment stages (the moment of surgically opening the phlegmon, on the 1st, 3rd and 7th postoperative days).
Perftoran considerably decreased the tissue hypoxia as well as the transaminase and creatinine levels in blood serum. Perftoran helped to decrease the intoxication indices, hypoxaemia by 10-15%, to speed local wound healing by 2-5 days and to shorten the time of hospital treatment by 3-6 days on average.
The many positive effects of perftoran on the clinical course of the disease and on a series of homeostatic parameters allow us to recommend that this drug to be added for treating patients having odontogenous phlegmons in the maxillofacial region.
